Literature DB >> 1184735

A radioimmunoassay for serum rat thyroglobulin. Physiologic and pharmacological studies.

A J Van Herle, H Klandorf, R P Uller.   

Abstract

A double antibody radioimmunoassay has been developed to measure thyroglobulin in rat (RTg) serum. The lowest detectable quantity measurable was 5.0 ng/ml. Specificity was documented by: (a) fall in serum RTg to undetectable levels after thyroid ablation; (b) the fact that L-thyroxine, D-thyroxine, L-triiodothyronine, D-triiodothyronine, triiodothyroacetic acid, tetraiodothyroacetic acid, triiodothyropropionic acid, moniodotyrosine, diiodotyrosine, and human thyroglobulin (HTg) in concentrations up to 40,000 ng per tube did not cross-react in the assay; (c) the demonstration that constant levels of serum RTg were observed while varying amounts of serum (criterion of parallelism) were introduced in the assay. The mean RTg concentration in tail vein blood of adult Sprague-Dawley rats were 101.5 +/- 13.0 ng/ml (SEM) (n=21); values ranged from 12.0 to 258.0 ng/ml. Chronic administration of a high-iodine diet (HID) did not affect serum thyroglobulin levels. Chronic administration of a low-iodine diet (LID) and propylthiouracil (PTU) led to a statistically significant increase in serum RTg that was accompanied by a significant rise in serum thyrotropin (rTSH). Serum thyroxine (T4) administered to normal rats for 14 days (20 mug/day subcutaneously) depressed serum RTg concentration from a mean level of 119.4 +/- 17.5 ng/ml (n=19) to a mean of 35.0 +/- 0.27 ng/ml (n=19) (P less than 0.001). While rats were on continuous T4 suppression, bovine thyroid-stimulating hormone (bTSH) given intravenously (2 IU) resulted in a mean maximal increment of RTg of 332.0 +/- 81.5 ng/ml (n=6) at 24 h. IgC-(LATS) long-acting thyroid stimulatory injected intravenously resulted in a mean maximal increment of RTg concentration at 96 h of 87.2 +/- 14.3 ng/ml (n=5). Normal IgG had no statistical significant effect of RTg levels at any time after the injection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1184735      PMCID: PMC301968          DOI: 10.1172/JCI108181

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  The effects of propylthiouracil and perchlorate on the biogenesis of thyroid hormone.

Authors:  J B RICHARDS; S H INGBAR
Journal:  Endocrinology       Date:  1959-08       Impact factor: 4.736

2.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

3.  GLUCOCORTICOID-INDUCED DISAPPEARANCE OF LONG-ACTING THYROID STIMULATOR IN THE OPHTHALMOPATHY OF GRAVES' DISEASE.

Authors:  N J SNYDER; D E GREEN; D H SOLOMON
Journal:  J Clin Endocrinol Metab       Date:  1964-11       Impact factor: 5.958

4.  Thyroid-stimulating hormone.

Authors:  H D PURVES; D D ADAMS
Journal:  Br Med Bull       Date:  1960-05       Impact factor: 4.291

5.  The effect of iodide on the release of thyroid hormone in hyperthyroidism.

Authors:  R E GOLDSMITH; M L EISELE
Journal:  J Clin Endocrinol Metab       Date:  1956-01       Impact factor: 5.958

6.  The effect of stable iodide on thyroid secretion in man.

Authors:  L J DEGROOT; M A GREER
Journal:  Metabolism       Date:  1956-11       Impact factor: 8.694

7.  Factors affecting the fractional rate of release of radioiodine from the thyroid gland in man.

Authors:  D H SOLOMON
Journal:  Metabolism       Date:  1956-11       Impact factor: 8.694

8.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

9.  Concentration of long-acting thyroid stimulator (LATS) by subfractionation of gamma G globulin from Graves' disease serum.

Authors:  K Miyai; S C Werner
Journal:  J Clin Endocrinol Metab       Date:  1966-05       Impact factor: 5.958

10.  The lymphatic and venous pathways for the outflow of thyroxine, iodoprotein and inorganic iodide from the thyroid gland.

Authors:  P M Daniel; L G Plaskett; O E Pratt
Journal:  J Physiol       Date:  1967-01       Impact factor: 5.182

View more
  10 in total

1.  Effect of therapy on the serum thyroglobulin concentration in patients with toxic diffuse goiter, toxic nodular goiter and toxic adenoma.

Authors:  U B Ericsson; L Tegler; J F Dymling; J I Thorell
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

2.  Mechanisms for increased adenylate cyclase responsiveness to TSH in neoplastic human thyroid tissue.

Authors:  O H Clark; P L Gerend; R A Nissenson
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

3.  Evidence for autonomous thyroglobulin release from euthyroid and hyperthyroid nodular goiter--thyroglobulin, a possible helpful parameter in diagnosis of non-malignant thyroid disorders.

Authors:  R Gärtner; A Hainzinger; K Horn; R C Pickardt
Journal:  Klin Wochenschr       Date:  1983-08-01

4.  [Thyroglobulin content of the blood in cases of hanging].

Authors:  E Müller; C Erfurt; W G Franke
Journal:  Z Rechtsmed       Date:  1990

5.  Extrathyroidal release of thyroid hormones from thyroglobulin by J774 mouse macrophages.

Authors:  K Brix; V Herzog
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

6.  Orphenadrine citrate (Norflex) mediated inhibition of thyroid function in the adult male rat.

Authors:  A J Van Herle; N Panagiotis; R Naruse; L Freisleben; H M Van Herle
Journal:  J Endocrinol Invest       Date:  1981 Apr-Jun       Impact factor: 4.256

7.  Antigen-specific B-cell function in human autoimmune thyroiditis.

Authors:  E De Bernardo; T F Davies
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

8.  Serum thyroglobulin in thyroid carcinoma and other thyroid disorders.

Authors:  F Pacini; A Pinchera; C Giani; L Grasso; F Doveri; L Baschieri
Journal:  J Endocrinol Invest       Date:  1980 Jul-Sep       Impact factor: 4.256

9.  Thyroid nodules and thyroid cancer: surgical aspects.

Authors:  O H Clark
Journal:  West J Med       Date:  1980-07

10.  Extracellularly occurring histone H1 mediates the binding of thyroglobulin to the cell surface of mouse macrophages.

Authors:  K Brix; W Summa; F Lottspeich; V Herzog
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.